New research indicates a potential therapeutic target for castration-resistant prostate cancer: RORĪ³, which is abundant in the disease, can drive androgen receptor hyperactivity. Blocking RORĪ³ with small-molecule antagonists suppresses AR and impedes tumor growth in mice bearing human prostate tumors, including a model resistant to the antiandrogen enzalutamide.
Cancer discovery. 2016 Apr 18 [Epub ahead of print]